Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gynecologic 3

Conditions

Ovarian Neoplasms 208Carcinoma, Ovarian Epithelial 133Fallopian Tube Neoplasms 117Uterine Cervical Neoplasms 103Breast Neoplasms 76Endometrial Neoplasms 73Pancreatic Neoplasms 33Neoplasms 31Colonic Neoplasms 28Stomach Neoplasms 27Carcinoma, Non-Small-Cell Lung 27Prostatic Neoplasms 26Testicular Neoplasms 24Sarcoma 23Lung Neoplasms 23Melanoma 22Carcinoma, Renal Cell 22Rectal Neoplasms 21Colorectal Neoplasms 20Vaginal Neoplasms 18Uterine Cervical Dysplasia 18Carcinoma, Hepatocellular 18Neoplasm Metastasis 17Anus Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Esophageal Neoplasms 16Brenner Tumor 16Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Vulvar Neoplasms 14

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Recurrent Uterine Sarcoma × Gynecologic × Clear all
NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT00238121 2015-11-20

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡